Mid-Atlantic
SPI Pharma Inc., in Lewes, has submitted an application to DNREC for renewal of a permit allowing its production facility to discharge treated process wastewater into the Delaware Bay and stormwater in the Lewes-Rehoboth Canal. CHRIS FLOOD PHOTO

DE - SPI Pharma seeks renewal of bay, canal discharge permit

SPI Pharma has applied for reissuance of a permit that allows the Lewes-based production facility to discharge treated process wastewater into the Delaware Bay and stormwater in the Lewes-Rehoboth Canal.

According to a June 3 public notice from Delaware Department of Natural Resources and Environmental Control’s Division of Water, SPI Pharma, 40 Cape Henlopen Drive, produces calcium carbonate, magnesium hydroxide and aluminum hydroxide, which are used in the manufacture of antacid medication. The company opened its Lewes facility in 1969.

According to a fact sheet related to permit renewal, SPI Pharma has four discharge sites – one for treated process wastewater site into the bay and three stormwater sites into mosquito control ditches that drain into the canal. The processed wastewater consists of gravity sedimentation and necessary pH adjustments in the ponds prior to discharge. The permit for the wastewater is based on a discharge rate of 2.64 million gallons per day.

Based on a preliminary staff review and application of lawful standards and regulations, the department proposes to re-issue this permit, subject to certain effluent limitations and conditions. The proposed determinations are tentative.

Read the full story here.